Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells

BACKGROUND: The monocarboxylate transporter-1 (MCT1) represents a novel target in rational anticancer drug design while AZD3965 was developed as an inhibitor of this transporter and is undergoing Phase I clinical trials (http://www.clinicaltrials.gov/show/NCT01791595). We describe the optimisation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kershaw, Stephen, Cummings, Jeffrey, Morris, Karen, Tugwood, Jonathan, Dive, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Technical Advance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436118/
https://www.ncbi.nlm.nih.gov/pubmed/25957999
http://dx.doi.org/10.1186/s12885-015-1382-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436118/
https://www.ncbi.nlm.nih.gov/pubmed/25957999
http://dx.doi.org/10.1186/s12885-015-1382-y

Ejemplares similares